Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Arrowhead Pharmaceuticals IncARWR | $88.70 | Strong Buy | $115.00 | +29.65% | 16 hours ago | |
Analyst RankingTop 4% #182 out of 5332 analysts Average Return+18.81% Win Rate40%119 out of 301 Risk vs RewardPoor Good Analyst ColorChardan Capital's Keay Nakae raised their price target on Arrowhead Pharmaceuticals (NASDAQ: ARWR) by 27.8% from $90 to $115 on 2026/07/22. The analyst maintained their Strong Buy rating on the stock. Nakae said their price target hike was catalyzed when Arrowhead Pharmaceuticals announced that both the SHASTA-3 and SHASTA-4 Phase 3 studies of plozasiran in severe hypertriglyceridemia met their primary endpoint. The data confirmed the "central pillar of Chardan Capital's Top Pick thesis" that plozasiran delivers best-in-class efficacy and safety in sHTG, the analyst explained. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | 2 days ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.